Roth Capital Downgrades Aeolus Pharmaceuticals (AOLS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts AOLS Hot Sheet
Price: $0.00 --0%
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 19
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 19
Join SI Premium – FREE
Roth Capital downgraded Aeolus Pharmaceuticals (OTCBB: AOLS) from Buy to Neutral with a price target of $1.00 (from $3.00).
For an analyst ratings summary and ratings history on Aeolus Pharmaceuticals click here. For more ratings news on Aeolus Pharmaceuticals click here.
Shares of Aeolus Pharmaceuticals closed at $0.30 yesterday.
For an analyst ratings summary and ratings history on Aeolus Pharmaceuticals click here. For more ratings news on Aeolus Pharmaceuticals click here.
Shares of Aeolus Pharmaceuticals closed at $0.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Brookfield India REIT (BIRET:IN) to Underweight
- UBS Downgrades Domino\'s Pizza Enterprises Ltd. (DMP:AU) (DPZUF) to Neutral
- Goldman Sachs Downgrades Sonic Healthcare Ltd. (SHL:AU) (SKHHY) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
